相关实验视频

Updated: Feb 28, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

患有MASLD和肝酶升高的患者的动态FIB-4评分变化和HCC风险:全国性队列研究

Yee Hui Yeo¹, Hsiu J Ho², Tsai-Wei Huang^3,4

¹Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

|February 26, 2026

概括

在FIB-4得分的连续变化可以预测肝细胞癌 (HCC) 风险在患有代谢功能障碍相关的脂肪性肝病 (MASLD) 的患者. 持续高的FIB-4分数显著增加HCC风险,突出显示需要监测.

科学领域:

肝病学肝病学是一种肝病学.
在瘤学瘤学.
非侵入性诊断是一种非侵入性诊断.

背景情况:

与代谢功能障碍相关的脂肪性肝病 (MASLD) 增加了肝细胞癌 (HCC) 的风险,即使没有肝硬化.
目前在MASLD患者中对HCC的查方法有限.
在MASLD患者中肝酶升高表明HCC发育的风险较高.

研究的目的:

调查三年内FIB-4分数的连续变化与非肝硬化MASLD患者的HCC风险之间的关联.
为了评估串行FIB-4得分变化的预测准确性,与HCC发展的单次测量相比.
在MASLD人群中确定需要针对性HCC监测的高风险患者群体.

主要方法:

利用来自国家医疗保险研究数据库 (NHIRD) 的810,698名MASLD患者的全国队列.
在3年的随访期间分析了FIB-4得分转变 (低风险,不确定的风险,高风险).
雇员竞争风险建模以估计HCC和死亡率的分分布危险比率 (SHR).

主要成果:

与单次测量相比,连续FIB-4评分变化显示HCC风险的预测准确度高于单次测量.
持久高FIB-4评分 (高至高) 的患者显示,与持久低评分 (低至低) 的患者相比,HCC风险增加了14倍 (aSHR 13.91).
恶化FIB-4分数 (例如,低至高) 逐渐增加HCC风险,而改善分数 (高至低) 与高至高组相比降低了HCC风险.

结论:

连续FIB-4评分监测准确地识别了非肝硬化MASLD患者肝酶升高的HCC高风险个体.
针对性HCC监测是有必要的,对于患者表现出持续高或恶化的FIB-4得分.
这种方法提供了一个更精确和可扩展的查工具,用于MASLD人群中的HCC.

关键词:

糖尿病糖尿病糖尿病在FIB-4中,FIB-4的位置是什么?肝癌是一种肝癌.公共卫生公共卫生连续测量系列测量

更多相关视频

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

相关概念视频

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...